- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: Pelvic floor physical therapy.
Displaying page 1 of 1.
EudraCT Number: 2017-001296-23 | Sponsor Protocol Number: 61409 | Start Date*: 2019-06-03 |
Sponsor Name:Radboudumc | ||
Full Title: The efficacy of botulinum toxin A injection in pelvic floor muscles in chronic pelvic pain patients: a double-blinded randomised controlled trial | ||
Medical condition: Patients with >6 months or recurrent episodes of abdomino-perineo-pelvic pain, hypersensitivity or discomfort often associated with elimination changes, and sexual dysfunction in the absence of org... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003381-40 | Sponsor Protocol Number: BED-PSMA-301 | Start Date*: 2020-06-22 | |||||||||||
Sponsor Name:Blue Earth Diagnostics Ireland Ltd. | |||||||||||||
Full Title: A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with newly diagnosed prostate cancer | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005935-14 | Sponsor Protocol Number: 3200K1-3358-WW | Start Date*: 2009-04-24 | |||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. | |||||||||||||
Full Title: An Open-Label Study to Evaluate the Long-term Safety of Subcutaneous MOA-728 for Treatment of Opioid-Induced Constipation in Subjects With Nonmalignant Pain Estudio abierto para evaluar la segurida... | |||||||||||||
Medical condition: Opioid-induced constipation in subjects with non-malignant pain Tratamiento del estreñimiento inducido por opiáceos en sujetos con dolor de origen no maligno | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000910-12 | Sponsor Protocol Number: HT011 | Start Date*: 2020-07-01 | |||||||||||
Sponsor Name:Helperby Therapeutics Ireland Limited | |||||||||||||
Full Title: A Double-blinded, Parallel-group, Randomized, Active-controlled Phase 2 Clinical Trial to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous HY-001 Versus Standard Colis... | |||||||||||||
Medical condition: complicated urinary tract infection (cUTI). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003671-35 | Sponsor Protocol Number: SPR994-301 | Start Date*: 2019-04-18 | |||||||||||
Sponsor Name:Spero Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) ... | |||||||||||||
Medical condition: complicated urinary tract infection or acute pyelonephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LV (Completed) BG (Completed) HU (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000657-39 | Sponsor Protocol Number: 0217/DEV | Start Date*: 2017-08-15 | |||||||||||
Sponsor Name:Develco Pharma Schweiz AG | |||||||||||||
Full Title: Randomised, double-blind, placebo-controlled, parallel-group, multi-centre, phase III trial to investigate the efficacy, safety and tolerability of Naloxone HCl PR Tablets in patients with opioid i... | |||||||||||||
Medical condition: Opioid induced constipation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) SK (Completed) ES (Completed) BG (Completed) PT (Completed) GB (Completed) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003772-31 | Sponsor Protocol Number: IT001-302 | Start Date*: 2018-12-07 |
Sponsor Name:Iterum Therapeutics International Limited | ||
Full Title: A prospective, Phase 3, randomized, multi-center, double-blind, double dummy study of the efficacy, tolerability and safety of intravenous sulopenem followed by oral sulopenem-etzadroxil with probe... | ||
Medical condition: Complicated urinary tract infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) HU (Completed) EE (Completed) CZ (Completed) BG (Completed) SK (Completed) HR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020821-41 | Sponsor Protocol Number: MDV3100-03 | Start Date*: 2011-02-10 | |||||||||||
Sponsor Name:Medivation, Inc., a wholly owned subsidiary of Pfizer Inc. | |||||||||||||
Full Title: PREVAIL: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer W... | |||||||||||||
Medical condition: Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (Completed) NL (Completed) ES (Completed) SE (Completed) AT (Completed) FI (Completed) DK (Completed) SK (Completed) IT (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003333-42 | Sponsor Protocol Number: EZH-302 | Start Date*: 2020-11-09 | |||||||||||
Sponsor Name:Epizyme, Inc. | |||||||||||||
Full Title: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refr... | |||||||||||||
Medical condition: Relapsed/refractory follicular lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
